MYocardial DOmmages Related to COVID-19
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 273
- Locations
- 1
- Primary Endpoint
- characterize the myocardial damage associated with CoV-2 SARS infection
Study Overview
Brief Summary
Myocardial injury, as assessed by elevation of cardiac troponins (Tnc), is frequent among patients with COVID-19. Although rare autopsy cases reported COVID-19 related myocardial inflammation, the origin of Tnc elevation is unknown to date. Several cardiac causes, such as myocarditis, non-ischemic myocardial injury (NIMI), or myocardial infarction (MI) may lead to Tnc kinetic. Our work will test the hypothesis that during SARS-Cov2 infection, the elevation of cardiac biomarkers could be linked to the occurrence of myocarditis.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •COVID-19 positive patient hospitalized < 72 h after symptoms onset with troponin assessement.
Exclusion Criteria
- •patients hospitalized > 72h after symptom onset
Outcomes
Primary Outcomes
characterize the myocardial damage associated with CoV-2 SARS infection
Time Frame: Through study completion, an average of 2 years
Myocardtitis diagnosis in patients COVID+ and troponin+
Secondary Outcomes
No secondary outcomes reported
